PUBLISHER: Grand View Research | PRODUCT CODE: 1362933
PUBLISHER: Grand View Research | PRODUCT CODE: 1362933
The global newborn screening market size is expected to reach USD 1.40 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 7.54% from 2023 to 2030. The growth of the market for newborn screening is majorly attributed to favorable reimbursement policies and government support programs, as well as the presence of key players focusing on developing efficient screening tests. In addition, high birth rates in the most populous economies such as China and India, coupled with high disposable income, are factors anticipated to drive the market positively.
According to Indian Paediatrics Report 2022, NBS has become a staple in public health prevention, and its panel is always growing. Specific DBS-based metabolic testing tools continue to be crucial in NBS. Genetic and genomic testing have become effective tools because of scientific advancements. Both, however, have advantages and drawbacks. The present NBS efficiency for some genetic illnesses will be increased by the integrated analysis of metabolic and genetic data, allowing more affected people to obtain early diagnosis and treatment, which will improve their prognosis.
In addition, government programs and legislation also create a favorable environment to foster market growth. The newborn screening program was recommended by the WHO to safeguard the health of children globally. Under this program, numerous policies and initiatives have been taken by the Japan's Society of Obstetrics and Gynecology (JSOG), U.S. Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), UK (PEACH), and advocacy groups like the March of Dimes.
Moreover, in June 2022, Novartis entered into a strategic partnership with the American Society of Hematology to deal with sickle cell disease amongst newborns in an additional six African countries. ASH's Consortium on Newborn Screening in Africa (CONSA) will provide early intervention and screening programs at several institutions in countries such as Ghana, Liberia, Kenya, Nigeria, Tanzania, Uganda, and Zambia.
Additionally, more focus on innovation in the field of newborn screening is expected to drive market growth. For instance, in August 2022, Trivitron Healthcare launched a Centre of Excellence for newborn screening, genomics, molecular diagnostics, and metabolomics. Cancer markers based on ELISA, PCR, and IVD CE-approved kits for newborn screening will be manufactured at the facility.